At molecular level, transient silencing experiments revealed that SIRT3 deficiency opposed the canagliflozin-mediated cytotoxicity, metabolic alterations and cell death mechanisms, thus reporting the first evidence of SGLT2/SIRT3 interaction in CRC. The gene discussed is SLC5A2; the disease is colorectal carcinoma.